2021 Press Releases Communiqués de presse
Sernova Announces the Nomination of Seasoned Pharma Executive Dr. Mohammad Azab to its Board of Directors
Sernova KOL Event Highlights Novel Cell Therapy Approach for the Potential Treatment of Thyroid Disease
Sernova to Host a Virtual Key Opinion Leader Event on Thyroid Disease and the Potential for its Cell Therapy as a Novel Treatment Approach
Sernova Appoints Internationally Renowned Thyroid Disease Expert Dr. Sam Wiseman to its Scientific Advisory Board
Sernova Announces Presentation at the American Diabetes Association 81st Scientific Sessions
Sernova Provides Positive Outlook Regarding the Development of Its Innovative Therapeutics Platform Technology for Chronic Diseases
SERNOVA ANNOUNCES CLOSING OF C$23 MILLION BOUGHT DEAL FINANCING INCLUDING FULL EXERCISE OF OVER-ALLOTMENT OPTION
Sernova Corp. Selected for the TSX Venture Stock Exchange’s 2021 Venture 50 List of Top Performing Listed Companies
Sernova Obtains Final Prospectus Receipt for $20 Million Bought Deal
Sernova Announces Second Annual Data Safety Monitoring Board Review of its Diabetes Cell Pouch System™ Clinical Trial and Recommendation for Protoco
Sernova Shares Accepted for Trading on the Electronic Trading Platform Xetra in Germany
Sernova Upsizes Previously Announced Bought Deal Public Offering to C$20 Million
Sernova’s Collaborator to Present Cell Pouch™ Thyroid Transplant Study Results at the American Association of Endocrine Surgeons 2021 Annual Meeti
Sernova Corp. Announces C$10 Million Bought Deal Offering of Units
Sernova Announces Collaboration Agreements with Multiple Pharmaceutical Industry Leaders
Sernova Announces Warrants Exercise for Proceeds of $4.3 Million and Early Conversion of Debenture
Sernova CEO to Present Regenerative Medicine Therapeutics Platform Update at the 2021 Cell & Gene Meeting on the Med
Sernova Principal Investigator Presents Additional Positive Preliminary Safety and Efficacy Data from Ongoing U.S. Phase I/II Cell Pouch Clinical Tria
Share the news Partagez les nouvelles
Press Release Communiqué de presse - May 04, 2021 4 May, 2021
Sernova Announces the Nomination of Seasoned Pharma Executive Dr. Mohammad Azab to its Board of Directors
May 4, 2021 9:00 AM ET
LONDON, ONTARIO – May 4, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a
leading
clinical-stage regenerative medicine therapeutics company, today announced that seasoned pharmaceutical
industry executive, Dr. Mohammad Azab, MB ChB, MSc, MBA, has been nominated by the Company to its
Board of Directors.
“Dr. Azab’s extensive knowledge and experience in the pharmaceutical industry, as well as his many industry
connections, make him an excellent fit for the Board of Sernova, particularly as the Company expands its
clinical development programs for the treatment of chronic diseases such as diabetes, thyroid and rare
diseases,” said Frank Holler, Chairman of the Board of Sernova. “Dr. Azab’s appointment further supports
the
Company’s near-term goal to bolster its Board of Directors, as well as Scientific Advisory and Global
Advisory
Boards, in line with our expanding research, development and business activities.”
Dr. Azab served as President and Chief Medical Officer of Astex Pharmaceuticals, Inc., a pharmaceutical
company focused on the discovery and development of drugs in oncology and other disease indications. As
of November 2020, upon retirement from his management role, Dr. Azab has served as the Chair of the
Board of Directors for Astex Pharmaceuticals, Inc, which is now a wholly-owned subsidiary of Otsuka
Pharmaceuticals. Previously, Dr. Azab served as President and CEO of Intradigm Corporation, a developer
of siRNA cancer therapeutics. Prior to this, Dr. Azab served as Executive Vice President of Research and
Development and Chief Medical Officer of QLT Inc., and in several leadership positions at AstraZeneca in
the United Kingdom and Sanofi Pharmaceuticals in France. Dr. Azab holds his medical degree (MB ChB)
from Cairo University and an MBA from the Richard Ivey School of Business, Western University, Ontario. He
received post-graduate training and degrees in oncology research from the University of Paris-Sud and
biostatistics from the University of Pierre et Marie Curie in Paris, France.
“I am excited to be nominated to join Sernova’s Board of Directors,” said Dr. Mohammad Azab. “I intend to
bring my experience and additional perspectives to support Sernova and its management team as the
company progresses it novel regenerative medicine therapeutic programs with the aim to provide a
‘functional cure’ for patients suffering from chronic diseases.”
Dr. Azab has more than 30 years of experience in clinical research, business management and led the global
development of several drugs currently approved in oncology and other therapeutic areas. Currently, he also
serves on the board of directors of NASDAQ listed companies, Xenon Pharmaceuticals Inc. (XENE), and
Durect Corporation (DRRX).
ABOUT SERNOVA
Sernova is developing regenerative medicine therapeutic technologies using its Cell Pouch medical device,
therapeutic cells (i.e., human donor cells, corrected human cells, stem cell-derived cells and tissues) and
immune protection technologies to improve the treatment and quality of life of people living with chronic
metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other
diseases treated through replacement of proteins or hormones missing or in short supply within the body.
For more information, please visit www.sernova.com.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dominic Gray
Sernova Corp.
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are
not historical facts and are generally, but not always, identified by the words "expects", "plans",
"anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that
events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the
expectations expressed in such forward-looking statements are based on reasonable assumptions, such
statements are not guarantees of future performance, and actual results may differ materially from those in
forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions
of Sernova’s management on the date such statements were made, which include our beliefs about the
conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or
revise any forward-looking statements whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - April 28, 2021 28 April, 2021
Sernova KOL Event Highlights Novel Cell Therapy Approach for the Potential Treatment of Thyroid Disease
April 28, 2021 9:00 AM ET
LONDON, ONTARIO – April 28, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a
leading clinical-stage regenerative medicine therapeutics company, announced today the highlights of its
first virtual Key Opinion Leader (KOL) event on thyroid disease.
The KOL event featured a presentation by Dr. Sam Wiseman, a leading surgeon and internationally
recognized expert in the management of thyroid and parathyroid disease. In his presentation, Dr. Wiseman
discussed current treatment options and the potential for a novel cell therapy approach for the treatment of
postoperative hypothyroidism using Sernova’s Cell Pouch™. The presentation was followed by a Q&A session
with attendees.
“I’m very excited about this program because as surgeons, we will be able to offer our patients a treatment
option that could allow for avoidance of postoperative hypothyroidism requiring life-long dependence on
thyroid medication,” said Dr. Sam Wiseman. “Our preclinical study evaluating transplantation of human
thyroid tissue into Sernova’s Cell Pouch has shown promising results. I believe this very exciting new
approach represents a critical step towards an entirely new treatment option for post-thyroidectomy
hypothyroidism."
Dr. Wiseman's presentation and the subsequent Q&A session are now available on Sernova's website at
www.sernova.com and on Sernova’s social media channels.
ABOUT SERNOVA'S THYROID PROGRAM
Sernova's approach for treating postoperative hypothyroidism is to transplant a portion of the thyroid gland
being removed into a pre-implanted vascularized Cell Pouch™ to recover thyroid function. In collaboration
with Dr. Wiseman, preclinical proof of concept study conducted under a grant from the British Columbia
Transplant Foundation is contributing to advancing Sernova's plans to conduct clinical assessment of this
novel approach. Sernova's overall treatment goal is to preserve thyroid function, and improve patient
quality of life, relative to current treatments.
Thyroidectomy is commonly performed for management of cancer, and for treatment of benign (non-
cancerous) disease that includes nodules, goitre and hyperthyroidism. It is estimated that about 150,000
thyroidectomies are performed in the US annually, with most individuals undergoing thyroid surgery
eventually being diagnosed with benign conditions. Patients undergoing total thyroidectomy, and many
patients undergoing partial thyroidectomy, require life-long oral postoperative thyroid hormone
replacement.
Post-surgical thyroid hormone replacement therapy, if monitored carefully, can be effective; however, some
patients may suffer from deleterious side-effects including body weight gain, fatigue, and depression, with a
resultant negative impact on quality of life, and significant costs to the healthcare system. We believe
Sernova's development of new therapeutic strategies to treat post-surgical hypothyroidism has the potential
of addressing an important unmet medical need.
ABOUT SERNOVA
Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells, stem cell-derived cells and
tissues) to improve the treatment and quality of life of people with chronic metabolic diseases such as
insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through
replacement of proteins or hormones missing or in short supply within the body. For more information,
please visit www.sernova.com.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dominic Gray
Sernova Corp.
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are
not historical facts and are generally, but not always, identified by the words "expects", "plans",
"anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that
events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the
expectations expressed in such forward-looking statements are based on reasonable assumptions, such
statements are not guarantees of future performance, and actual results may differ materially from those in
forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions
of Sernova's management on the date such statements were made, which include our beliefs about the
conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or
revise any forward-looking statements whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - April 21, 2021 21 April, 2021
Sernova to Host a Virtual Key Opinion Leader Event on Thyroid Disease and the Potential for its Cell Therapy as a Novel Treatment Approach
April 21, 2021 9:00 AM ET
LONDON, ONTARIO – April 21, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a
leading clinical-stage regenerative medicine therapeutics company, today announced that it will host a virtual
Key Opinion Leader (KOL) event on thyroid disease, current treatment options and the potential of a novel cell
therapy treatment approach for postoperative hypothyroidism. The event will take place on Tuesday April 27th,
2021, at 1:00 PM ET.
The event will feature a presentation from Dr. Sam Wiseman, a leading academic thyroid/parathyroid surgeon
and internationally recognized expert in the management of thyroid and parathyroid disease.
"This KOL event will provide the unique opportunity for our investors to learn about thyroid disease, current
treatments, and exciting advancements towards a novel cell therapy treatment approach aimed to provide a
functional cure for patients suffering from postoperative hypothyroidism," said Dr. Philip Toleikis, President
and CEO of Sernova. "Participants will also be able to enter into a conversation through a Q&A period with Dr.
Wiseman, a prominent physician in the management of thyroid disease."
Dr. Wiseman's presentation will be made available on Sernova's website before the call. All questions to Dr.
Wiseman, can be submitted to info@sernova.com prior to the call.
To register and access the Zoom link for this event, please click:
https://zoom.us/webinar/register/2016189463384/WN_LF8impNgRzqpbSMeLdeMww
Following the event, a recording will be available at www.sernova.com.
ABOUT SERNOVA'S HYPOTHYROID PROGRAM
Sernova's immediate approach in treating hypothyroid disease is to transplant healthy thyroid tissue following
thyroidectomy (removal of the thyroid gland) into the pre-implanted vascularized Cell Pouch to recover the
normal function of the thyroid gland. In collaboration with Dr. Wiseman, preclinical proof of concept work
conducted under a grant from the British Columbia Transplant Foundation is contributing to advancing
Sernova's plans to conduct clinical assessment of the Cell Pouch with transplanted thyroid tissue in patients
suffering from hypothyroid disease. Sernova's treatment goal is to preserve thyroid function and improve
patient quality of life relative to current treatments.
Thyroidectomy is commonly performed for cancer diagnosis or treatment and for treatment of benign (non-
cancerous) disease that includes goiter and hyperthyroidism. It is estimated that about 150,000
thyroidectomies are performed in the US yearly, and the majority of individuals undergoing a thyroid operation
are diagnosed with benign diseases after their procedure. Patients with Grave's disease and thyroid nodules
undergoing total thyroidectomy, and many patients undergoing partial thyroidectomy require life-long thyroid
hormone replacement.
Post-surgical thyroid hormone replacement therapy, if monitored carefully, can be effective; however, patients
often suffer from deleterious side-effects including weight gain, depression, headaches, and cardiovascular
disease, with resultant negative impact on quality of life, and significant costs to the healthcare system. We
believe Sernova's development of new therapeutic strategies to overcome hypothyroidism has the potential to
meet an important unmet medical need.
ABOUT SERNOVA
Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dominic Gray
Sernova Corp.
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates",
"believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions
"will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova's management on
the date such statements were made, which include our beliefs about the conduct and outcome of clinical
trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking
statements whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - April 14, 2021 14 April, 2021
Sernova Appoints Internationally Renowned Thyroid Disease Expert Dr. Sam Wiseman to its Scientific Advisory Board
Sernova Expands Scientific Advisory Board Expertise for its Innovative Cell Therapy Therapeutic Applications
in Endocrine Disorders Including Thyroid Disease
April 14, 2021 9:00 a.m. EST
LONDON, ONTARIO – April 14, 2021 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a
leading clinical-stage company developing regenerative medicine therapeutic technologies for the long-term
treatment of chronic diseases, today announced the appointment of Dr. Sam Wiseman to its Scientific Advisory
Board (SAB).
“We are pleased to welcome Dr. Wiseman to Sernova’s Scientific Advisory Board,” said Dr. Philip Toleikis,
President & CEO Sernova Corp. “Dr. Wiseman’s internationally recognized leadership in surgical treatment of
thyroid and parathyroid disease and his forward-thinking interest in Sernova’s development of novel cell
therapy-based applications will be a great asset as we seek to expand the clinical applications of our cell pouch
platform.”
“The importance of the thyroid gland in controlling everyday bodily functions is often underappreciated. For
people who have their thyroid gland removed, the solution relies on lifelong dependence on medication,” said
Dr. Sam Wiseman. “Sernova’s cell therapy approach aims at providing a functional cure and improving the
quality of life for these patients by allowing them to reduce or potentially eliminate daily thyroid hormone
treatments. I am excited to join Sernova’s Scientific Advisory Board and bring my expertise to support them in
the development of novel cell-based approaches for treatment of thyroid disease and potentially other
endocrine diseases.”
Dr. Sam Wiseman is an academic thyroid/parathyroid surgeon and internationally recognized expert in the
management of thyroid and parathyroid disease. He is Professor of Surgery in the Faculty of Medicine at the
University of British Columbia (UBC) and is an attending surgeon at St. Paul’s Hospital in Vancouver. Dr.
Wiseman attended medical school and completed residency training in General Surgery, at the University of
Manitoba, obtaining a Fellowship in Surgery from the Royal College of Physicians and Surgeons of Canada in
2000. At Roswell Park Cancer Institute, he completed fellowships in Head & Neck Surgery, Surgical Oncology,
and Oncology Research. Dr. Wiseman joined the staff at St. Paul's Hospital, and the University of British
Columbia in 2003. He is also a Fellow of the American College of Surgeons, and a Consultant Surgical
Oncologist at the British Columbia Cancer Agency (BCCA). He currently serves as the Research Head for the
Department of Surgery at Providence Health Care and is the Chair of the Endocrine Tumour Group of the
BCCA. He has authored more than 150 peer-reviewed scientific publications, numerous book chapters, and
served as a senior editor of the medical textbook, Gray’s Surgical Anatomy. Dr. Wiseman’s research has been
presented globally and he has received numerous awards and honours throughout his career that include a
Michael Smith Foundation for Health Research Scholar Award and Canada’s Top 40 Under 40 Award. He is
passionate about education and mentors and supervises many trainees, both clinically and in research. He is
committed to providing new therapeutic options and treatment approaches for patients suffering from
thyroid/parathyroid diseases with the ultimate goal of improving quality of life for these people.
ABOUT SERNOVA’S THYROID DISEASE PROGRAM
Sernova is utilizing its Cell Pouch Platform as a potential treatment for hypothyroid disease. Our approach is to
transplant a patient’s own healthy thyroid tissue following thyroidectomy into the pre-implanted vascularized
Cell Pouch to preserve the normal thyroid function and reduce or eliminate the need for lifelong daily thyroid
replacement therapy. Sernova plans to conduct clinical assessments of the Cell Pouch with transplanted thyroid
tissue in patients suffering from post-surgical hypothyroidism with the aim of preserving thyroid function and
improving patient quality of life.
Thyroidectomy is commonly performed for cancer diagnosis or treatment and for treatment of benign (non-
cancerous) disease that includes goiter and hyperthyroidism. It is estimated that about 150,000
thyroidectomies are performed in the US yearly. Patients with Grave’s disease and thyroid nodules undergoing
total thyroidectomy, and many patients undergoing partial thyroidectomy require life-long thyroid hormone
medication. Post-surgical thyroid hormone replacement therapy, if monitored carefully, can be effective;
however, patients often suffer from deleterious side-effects including weight gain, depression, headaches, and
cardiovascular disease, with resultant negative impact on quality of life, and significant costs to the healthcare
system. The development of new therapeutic strategies to overcome hypothyroidism remains an important
unmet medical need.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells, and stem cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, hypothyroidism, hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com.
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - April 06, 2021 6 April, 2021
Sernova Announces Presentation at the American Diabetes Association 81st Scientific Sessions
April 6, 2021 9:00 am ET
LONDON, ONTARIO – April 6, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a
leading
clinical-stage regenerative medicine therapeutics company, is pleased to announce that lead principal
investigator Dr. Piotr Witkowski and the Clinical Trial Investigator Team for its US Phase I/II Type 1 Diabetes
clinical trial will present data and observations from the ongoing study in a poster presentation at the
upcoming
American Diabetes Association’s (ADA) 81st Scientific Sessions to be held June 25 - 29, 2021.
The abstract will also be published online at the journal Diabetes® website and the presentation will be
available to conference attendees on Friday, June 25, 2021.
Dr. Witkowski, Director, Pancreatic and Islet Transplant Program at the University of Chicago, is also
scheduled
to deliver a lecture titled “Islet Transplantation – Benefits and Shortcomings”, as part of the Clinical and
Regulatory Hurdles Facing Islet Transplantation session on Monday, June 28, 2021, at 8:00 am ET.
Note: all information contained in the submitted abstract should be considered preliminary and subject to
change until the study data and observations are fully presented at the ADA 81st Scientific Sessions and is
subject to embargo until June 25, 2021, at 11:30 am ET.
ABOUT SERNOVA’S CELL POUCH SYSTEM
The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro-
encapsulation device solution designed for the long-term survival and function of therapeutic cells. The
device
upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for
the
transplantation and function of therapeutic cells, which then release proteins and hormones as required to
treat disease. The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and
efficacy in small and large animal models of diabetes and has been proven to provide a biologically
compatible
environment for insulin-producing cells in humans.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and
immune
protected therapeutic cells ( i.e. human donor cells, corrected human cells and stem cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-
dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins
or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com.
ABOUT THE ADA’s SCIENTIFIC SESSIONS
The American Diabetes Association’s (ADA) 81st Scientific Sessions, the world’s largest scientific meeting
focused on diabetes research, prevention, and care, will be held virtually June 25-29, 2021. Leading
physicians, scientists, and health care professionals from around the world will unveil cutting-edge research,
treatment recommendations and advances toward a cure for diabetes. Though the conference will be
remote
this year, attendees will receive exclusive access to nearly 2,000 original research presentations and take
part
in provocative and engaging exchanges with leading diabetes experts. Learn more and register at
scientificsessions.diabetes.org and join the Scientific Sessions conversation on social media using
#ADA2021.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dominic Gray
Sernova Corp.
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are not recitations of historical facts, may
constitute
“forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without
limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible,
but
not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects",
"potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or
"should"
occur are used to identify forward-looking statements. These statements reflect management’s beliefs with
respect to future events and are based on information currently available to management on the date such
statements were made. Many factors could cause Sernova’s actual results, performances or achievements to
not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such factors could include, but are not limited
to,
the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at
all;
ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and/or
related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory
approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to
execute
its business strategy and successfully compete in the market; and the inherent risks associated with the
development of biotechnology combination products generally. Many of the factors are beyond our control,
including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should
consult
the company’s quarterly and annual filings available on www.sedar.com for additional information on risks
and
uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or
obligation to update or revise any forward-looking statements, whether as a result of new information,
future
events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - March 15, 2021 15 March, 2021
Sernova Provides Positive Outlook Regarding the Development of Its Innovative Therapeutics Platform Technology for Chronic Diseases
Sernova is the first and only regenerative medicine therapeutics platform company to demonstrate a well-
vascularized subcutaneous islet transplant technology achieving persistent islet graft function in diabetic
patients
Sernova CEO hosting an investor conference call on March 18, 2021 at 11:00 am (EDT)
March 15, 2021 9:00 a.m. EDT
LONDON, ONTARIO – March 15, 2021 – Sernova Corp. (TSX-V:SVA) (FSE/XETRA:PSH) (OTCQB:SEOVF), a
clinical-stage regenerative medicine company, today provides a Corporate Update and highlights recent key
achievements in its pipeline, including its diabetes clinical program as well as other leading development
programs.
“I am pleased that our clinical study based on our unique technology platform continues to contribute
significant advancements to the field of regenerative medicine therapeutics. This is demonstrated by ongoing
positive patient outcomes in safety, tolerability, and efficacy measures as we actively approach completion of
full study enrolment. These advancements are occurring despite ongoing global uncertainty related to the
COVID-19 pandemic. In this restrictive environment, Sernova also achieved significant advancements in our
other therapeutic programs and in the development of technologies that we believe are building significant
shareholder value and justified optimism for patients suffering from chronic diseases. As validation of our
strategic approach, we are pleased with the recently completed institutional led bought deal financing of $23M.
We are aggressively moving forward with all of our programs,” said Dr. Philip Toleikis, President and CEO of
Sernova.
DIABETES : SERNOVA’S LEAD CLINICAL INDICATION
Sernova’s principal investigator in its US Phase I/II diabetes clinical trial, Dr. Piotr Witkowski, presented an
update at the recent 2021 21st Winter Symposium of the American Society of Transplant Surgeons based on
data from its current clinical trial: A Safety, Tolerability and Efficacy -Study of Sernova's Cell Pouch for Clinical
Islet Transplantation.
Five of the 7 planned patients have been enrolled, implanted with the Cell Pouch, and are advancing through
the transplantation phases of the study.
The following key findings to date have been noted in our trial patients:
• The Primary Safety Endpoint of the study continues to be met:
o the Cell Pouch, following implantation under the skin, shows consistent incorporation with vascularized
tissue in multiple patients providing a suitable environment for the survival and function of insulin producing
cells; and
o the implanted Cell Pouch and therapeutic cells continue to demonstrate a positive safety profile with no
serious adverse events related to the Cell Pouch.
• The Secondary Efficacy measures continue to show clinical benefit in the most advanced treated patients
including:
o absence of life-threatening hypoglycemic episodes;
o enduring presence of insulin produced by the Cell Pouch transplanted cells (measured by the biomarker C-
peptide) in the bloodstream;
o reduction or elimination in the daily amount of insulin injected; and
o a reduction in HbA1c, a measure of long-term blood sugar control, which can lead to reduced diabetic
complications.
Pre-screening of the final two patients is actively underway to complete study enrollment.
HEMOPHILIA A
Sernova as a member of the Horizon 2020 HemAcure Consortium (HemAcure Consortium) presented results of
the Consortium’s research at the American Society of Gene and Cell Therapy. Importantly, the following
highlights were presented:
• hemophilia A patients unable to express the required clotting factor VIII (FVIII) blood cells were isolated;
• the human FVIII gene responsible for the production of the missing required clotting factor was
successfully inserted to achieve a therapeutic effect;
• the safety of these newly corrected cells and their ability to produce sufficient human clotting factor both
in laboratory and in an initial preclinical animal model was confirmed.
o human FVIII blood levels reached up to 10%, which is considered sufficient to enable patients to regain
their clotting ability;
o these corrected therapeutic cells in the Cell Pouch were successfully assessed in a preclinical model of
hemophilia A showing long-term survival of cells;
o human FVIII was also detected in the bloodstream long-term (measured up to four months, the length of
the study, following treatment); and
• data further confirmed functional clotting improvement in the blood at the four months time point where
human FVIII corrected cells transplanted into the hemophilia A preclinical model restored the animals clotting
activity to a therapeutic level within the Cell Pouch.
“These results demonstrate the success in developing a novel approach for the treatment of hemophilia A.
These results continue to showcase Sernova’s Cell Pouch platform technologies for the treatment of multiple
indications including rare diseases where a gene can be inserted into cells to produce any protein or factor
required to treat disease,” added Toleikis. “We look forward to completing work to bring this and other novel
therapies to human clinical testing as soon as practicable.”
HYPOTHYROID DISEASE
Sernova is developing a treatment for hypothyroid disease following complete or partial removal of the thyroid
gland (thyroidectomy). To advance this platform technology, in collaboration with Dr. Sam Wiseman and in part
funded by a Transplant Venture Grant awarded by the Transplant Research Foundation (TRF) of British
Columbia, we are assessing healthy human thyroid tissue in preparation of a clinical program.
This new treatment approach allows patients to preserve their thyroid function following a thyroidectomy by
transplanting healthy thyroid cells into Sernova’s Cell Pouch. Currently completed pre-clinical work is setting
the stage for a regulatory submission for this second clinical program.
PLATFORM EXPANDING TECHNOLOGIES AND CORPORATE COLLABORATIONS
Sernova is acquiring and developing state of the art technologies. These involve both unique cell encapsulating
technologies and gene editing technologies to reduce or eliminate the need for immunosuppression
medications targeted to our specific cell therapy clinical applications within the Cell Pouch platform.
• Sernova has acquired all the patented technology and knowhow for a cellular local immune protection
technology (Conformal Coating Technology)
o an exclusive worldwide license agreement with the University of Miami was signed, broadening this
technology scope.
o Sernova intends on bringing the Cell Pouch platform technologies, which includes conformally coated
therapeutic cell technology, to the clinic first for our diabetes donor and stem cell programs with the goal to
improve current cell therapy treatment options.
• Sernova also entered into a collaboration agreement with AgeX Therapeutics to utilize their UniverCyte™
technology. The objective is to generate transplantable genetically engineered stem cells that are immune
protected to treat diseases for use in Sernova’s Cell Pouch.
Sernova is in active collaborations with leading global pharmaceutical companies for multiple cell therapy
clinical applications in combination with Sernova’s cell therapy therapeutic platform and technologies. The goal
of these collaborations is to initiate co-development and/or licensing agreements, as well as the potential
ability to market and distribute our regenerative medicine therapeutics worldwide.
Dr. Toleikis will participate in the first of a series of conference calls for shareholders to provide corporate
updates and answer questions at 11:00 am (EDT) on March 18, 2021. A presentation will be made available on
Sernova’s website before the call. All questions to Dr. Toleikis can be submitted to info@sernova.com prior to
the call. To participate in this live conference call, please visit:
Meeting link:
https://sernovacorp.my.webex.com/sernovacorp.my/j.php?MTID=md016888548d385cd4fea3878b73a9b5d
Meeting number: 182 490 4245
Password: SVAMarch2021 (78262724 from phones and video systems)
Join by phone
+1-416-915-6528 CANADA TOLL
+1-415-655-0001 US TOLL
Access code: 182 490 4245
(Global call-in numbers available upon request)
Following the conference call a recording will be available at www.sernova.com
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information, please contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - March 01, 2021 1 March, 2021
SERNOVA ANNOUNCES CLOSING OF C$23 MILLION BOUGHT DEAL FINANCING INCLUDING FULL EXERCISE OF OVER-ALLOTMENT OPTION
LONDON, ONTARIO – March 1, 2021 – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB:
SEOVF) (Frankfurt/Xetra: PSH), a leading clinical-stage regenerative medicine therapeutics company, is
pleased to announce that it has closed its previously announced bought deal financing of 16,700,000 units of
the Company (the “Units”) at a price of C$1.20 per Unit (the “Issue Price”), and the exercise in full of the
Over-Allotment Option of 2,505,000 Units at the Issue Price, for aggregate gross proceeds to the Company
of approximately C$23,046,000 (the “Offering”).
Each Unit is comprised of one common share of the Company (a “Common Share”) and one Common Share
purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share
(as “Warrant Share”) at an exercise price of C$1.70 (the “Exercise Price”) until March 1, 2023. The expiry
date of the Warrants may be accelerated by the Company if the daily volume weighted average trading price
of the Common Shares on the TSX Venture Exchange (the “Exchange”) is greater than C$3.05 for the
preceding ten (10) consecutive trading days, at which time the Company may accelerate the expiry date of
the Warrants by providing notice to the holders of Warrants or issuing a news release announcing such
acceleration, whereupon the Warrants will expire not less than 30 days after the date of such notice or news
release.
The Offering was conducted on a “bought deal” basis, led by Canaccord Genuity Corp. and Leede Jones
Gable Inc. as co-lead underwriters (together, the “Underwriters). As consideration for their services in
connection with the Offering, the Company paid to the Underwriters: (i) a cash commission of $1,452,981;
(ii) a corporate finance fee of 384,100 Units; and (iii) 1,210,818 compensation options (the “Compensation
Options”), where each Compensation Option entitles the holder thereof to purchase one Unit (a
“Compensation Unit”) at the Issue Price until March 1, 2023. Each Compensation Unit is comprised of one
Share and one Warrant exercisable into a Warrant Share at the Exercise Price.
The net proceeds of the Offering will be used to advance the Company’s clinical development programs, including its US Phase I/II Cell Pouch clinical trial in insulin-dependent diabetes, expand the Company’s
research and development programs, including its local immune protection technologies for the Cell Pouch,
as well as for working capital and general corporate purposes.
The Offering was completed (i) by way of a short form prospectus filed in each of the provinces of Canada,
other than Quebec, pursuant to National Instrument 44-101 – Short Form Prospectus Distributions, (ii) on a
private placement basis in the United States pursuant to exemptions from the registration requirements of
the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and applicable U.S. state
securities laws, and (iii) outside Canada and the United States on a basis which does not require the
qualification or registration of any of the Company’s securities under domestic or foreign securities laws.
The securities referred to in this press release have not been, nor will they be, registered under the U.S.
Securities Act or any U.S. state securities laws, and may not be offered or sold within the United States or to,
or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the
U.S. registration requirements. This press release does not constitute an offer for sale of securities, nor a
solicitation for offers to buy any securities in the United States, nor in any other jurisdiction in which such
offer, solicitation or sale would be unlawful. Any public offering of securities in the United States must be
made by means of a prospectus containing detailed information about the company and management, as
well as financial statements.
About Sernova Corp.
Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells, and stem cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-
dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement
of proteins or hormones missing or in short supply within the body. For more information, please visit
www.sernova.com.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dominic Gray
Sernova Corp
T: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Cautionary Statement Regarding Forward-Looking Information
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian
securities legislation. These statements relate to future events or future performance. The use of any of the
words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and
statements relating to matters that are not historical facts are intended to identify forward-looking
information and are based on Sernova’s current belief or assumptions as to the outcome and timing of such
future events. Forward looking information in this press release includes information with respect to the
intended use of proceeds by the Company. Forward-looking information is based on reasonable
assumptions that have been made by Sernova at the date of the information and is subject to known and
unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially
from those anticipated in the forward-looking information. Examples of such risk factors include: credit;
market (including equity, foreign exchange and interest rate); liquidity; operational (including technology and
infrastructure); reputational; insurance; strategic; regulatory; legal; environmental; capital adequacy; the
general business and economic conditions in the regions in which the Company operates; the ability of the
Company to execute on key priorities, including the successful development of its product candidates, and
strategic plans and to attract, develop and retain key executives; the ability to implement business strategies
and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on the Company's
information technology; the failure of third parties to comply with their obligations to the Company or its
affiliates; the impact of new and changes to, or application of, current laws and regulations governing the
Company’s business; dependence on key suppliers; granting of permits and licenses; increased competition;
changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and
competition for funding; the availability of funds and resources to pursue operations; critical accounting
estimates and changes to accounting standards, policies, and methods used by the Company; the
occurrence of natural and unnatural catastrophic events and claims resulting from such events; risks related
to COVID-19 including various recommendations, orders and measures of governmental authorities to try to
limit the pandemic, including travel restrictions, border closures, nonessential business closures,
quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, economic
activity, financing, supply chains and sales channels, and a deterioration of general economic conditions
including a possible national or global recession; as well as those risk factors disclosed under the heading
“Risk Factors” in the Company’s Annual Information Form (dated February 8, 2021) for the year ended
October 31, 2020, which has been filed on SEDAR and is available under the Company’s profile at
www.sedar.com. Given these risks, uncertainties and assumptions, you should not unduly rely on these
forward-looking statements. The forward-looking information contained in this press release is made as of
the date hereof, and Sernova is not obligated to update or revise any forward-looking information, whether
as a result of new information, future events or otherwise, except as required by applicable securities laws.
The foregoing statements expressly qualify any forward-looking information contained herein.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - February 25, 2021 25 February, 2021
Sernova Corp. Selected for the TSX Venture Stock Exchange’s 2021 Venture 50 List of Top Performing Listed Companies
February 25, 2021 9:00 a.m. EST
LONDON, ONTARIO - February 25, 2021 - Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF)
(Frankfurt/Xetra:PSH), a clinical-stage company and leader in regenerative medicine therapeutics is pleased
to announce that the TSX Venture Stock Exchange (TSX Venture) has recognized Sernova as a 2021 Venture
50 company, showcasing the top 50 performing listed companies.
“We are honoured to be chosen for the 2021 Venture 50 list and to be included amongst this distinguished
group of industry leaders. We share this honour with our institutional and retail investors who are supporting
our continued success and growth,” said Dr. Philip Toleikis, President and CEO of Sernova Corp. “This
recognition is another validation of Sernova’s ongoing therapeutic advancements and builds upon what will
be another very strong year as we continue to grow the company and build further shareholder value.”
The Venture 50 are the top ten companies listed on TSX Venture Exchange in each of five major industry
sectors – mining, energy & energy services, clean technology & life sciences, diversified industries and
technology – based on a ranking formula with equal weighting given to market cap growth, trading volume
amount and share price appreciation. All data was as of December 31, 2020.
ABOUT SERNOVA’S CELL POUCH SYSTEM
The Cell Pouch system including the Cell Pouch, which is a novel, proprietary, scalable, implantable macro-
encapsulation device solution designed for the long-term survival and function of therapeutic cells. The
device is designed to incorporate with tissue, forming highly vascularized tissue chambers for the
transplantation and function of therapeutic cells which then release proteins and hormones as required to
treat disease. The Cell Pouch along with therapeutic cells has been shown to provide long-term safety and
efficacy in small and large animal models of diabetes and has been proven to provide a biologically
compatible environment for insulin-producing cells in humans. In early assessments of its ongoing Phase I/II
clinical trial, Sernova has shown presence of blood levels of c-peptide both during glucose tolerance tests as
well as under fasting conditions. Clinical testing is ongoing at the University of Chicago.
ABOUT SERNOVA CORP
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and
immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived
cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-
dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement
of proteins or hormones missing or in short supply within the body. For more information, please visit
www.sernova.com
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are
not historical facts and are generally, but not always, identified by the words “expects”, “plans”,
“anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that
events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the
expectations expressed in such forward-looking statements are based on reasonable assumptions, such
statements are not guarantees of future performance, and actual results may differ materially from those in
forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions
of Sernova’s management on the date such statements were made, which include our beliefs about the
conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or
revise any forward-looking statements whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - February 24, 2021 24 February, 2021
Sernova Obtains Final Prospectus Receipt for $20 Million Bought Deal
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
LONDON, ONTARIO – February 24, 2021 – Sernova Corp. ("Sernova" or the "Company") (TSX-V: SVA)
(OTCQB: SEOVF) (Frankfurt/Xetra:PSH), a leading clinical-stage regenerative medicine therapeutics company,
is pleased to announce it has received a receipt for its final short form prospectus dated February 24, 2021 (the
"Final Prospectus") in connection with its previously announced bought deal offering of 16,700,000 units of the
Company (the "Units") at a price of C$1.20 per Unit for gross proceeds of approximately C$20,040,000 (the
"Offering"). Canaccord Genuity Corp. and Leede Jones Gable Inc. are the co-lead underwriters (together, the
"Underwriters") of the Offering.
The Company expects to close the Offering on or around March 1, 2021.
The Company has granted the Underwriters an option, exercisable in part or in whole at the Underwriter's sole
discretion, at any time until 30 days following closing, to purchase up to that number of additional Units equal
to 15% of the aggregate number of Units sold in the Offering.
The Final Prospectus was filed with the securities regulatory authorities in all provinces of Canada, except
Quebec, and is available under the Company's SEDAR profile at www.sedar.com.
The securities referred to in this press release have not been, nor will they be, registered under the U.S.
Securities Act or any U.S. state securities laws, and may not be offered or sold within the United States or to, or
for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S.
registration requirements. This press release does not constitute an offer for sale of securities, nor a solicitation
for offers to buy any securities in the United States, nor in any other jurisdiction in which such offer, solicitation
or sale would be unlawful. Any public offering of securities in the United States must be made by means of a
prospectus containing detailed information about the company and management, as well as financial
statements.
About Sernova Corp.
Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e., human donor cells, corrected human cells, and stem cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Cautionary Statement Regarding Forward-Looking Information
This press release contains 'forward-looking information' within the meaning of applicable Canadian securities
legislation. These statements relate to future events or future performance. The use of any of the words
"could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements
relating to matters that are not historical facts are intended to identify forward-looking information and are
based on Sernova's current belief or assumptions as to the outcome and timing of such future events. Forward
looking information in this press release includes information with respect to the Offering, including the timing
and ability of the Company to close the Offering, receipt of all regulatory and stock exchange approvals, the
intended use of proceeds by the Company and the exercise of the Over-allotment Option by the Underwriters.
Forward-looking information is based on reasonable assumptions that have been made by Sernova at the date
of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause
actual results or events to differ materially from those anticipated in the forward-looking information.
Examples of such risk factors include: the inability of the Company to close the Offering or to obtain all
necessary Exchange and regulatory approvals; credit; market (including equity, foreign exchange and interest
rate); liquidity; operational (including technology and infrastructure); reputational; insurance; strategic;
regulatory; legal; environmental; capital adequacy; the general business and economic conditions in the
regions in which the Company operates; the ability of the Company to execute on key priorities, including the
successful development of its product candidates, and strategic plans and to attract, develop and retain key
executives; the ability to implement business strategies and pursue business opportunities; disruptions in or
attacks (including cyber-attacks) on the Company's information technology; the failure of third parties to
comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application
of, current laws and regulations governing the Company’s business; dependence on key suppliers; granting of
permits and licenses; increased competition; changes in foreign currency rates; increased funding costs and
market volatility due to market illiquidity and competition for funding; the availability of funds and resources to
pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods
used by the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from
such events; risks related to COVID-19 including various recommendations, orders and measures of
governmental authorities to try to limit the pandemic, including travel restrictions, border closures,
nonessential business closures, quarantines, self-isolations, shelters-in-place and social distancing, disruptions
to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general
economic conditions including a possible national or global recession; as well as those risk factors disclosed
under the heading “Risk and Uncertainties” in the Company’s annual MD&A (dated February 1, 2021) for the
years ended October 31, 2020 and 2019, which has been filed on SEDAR and is available under the Company’s
profile at www.sedar.com. Given these risks, uncertainties and assumptions, you should not unduly rely on
these forward-looking statements. The forward-looking information contained in this press release is made as
of the date hereof, and Sernova is not obligated to update or revise any forward-looking information, whether
as a result of new information, future events or otherwise, except as required by applicable securities laws. The
foregoing statements expressly qualify any forward-looking information contained herein.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - February 18, 2021 18 February, 2021
Sernova Announces Second Annual Data Safety Monitoring Board Review of its Diabetes Cell Pouch System™ Clinical Trial and Recommendation for Protocol Continuation
Ongoing Safety of Sernova's Clinical Trial Confirmed
February 18, 2021 9:00 a.m. EST
LONDON, ONTARIO – February 18, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical-
stage company and leader in regenerative medicine therapeutics, is pleased to announce that the clinical trial
independent Data Safety Monitoring Board ("DSMB") has completed the second planned annual review of the
ongoing Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation Phase
I/II clinical trial in patients with severe hypoglycemia unawareness and inability to produce their own insulin.
The DSMB recommended that the Phase I/II clinical study should continue according to the study protocol and
any related amendments. In their assessment, the DSMB did not raise any concerns regarding patient safety.
"We are pleased with the second annual independent DSMB review of our Phase I/II clinical trial," said Dr.
Philip Toleikis, President & CEO Sernova Corp. "We thank the DSMB for its diligence, guidance and support as
Sernova continues progressing the clinical trial."
The DSMB is an independent group of clinical research experts who review the accumulated data to permit a
thorough evaluation of patient safety and to ensure the integrity of the study's data and progress towards
completion.
ABOUT SERNOVA'S CLINICAL TRIAL
Sernova is conducting a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial to assess
the safety and tolerability of islet transplantation into the company's patented Cell Pouch in diabetic subjects
with hypoglycemia unawareness and an inability to produce their own insulin. The secondary objective is to
assess efficacy through a series of defined measures. Eligible subjects are implanted with Cell Pouches.
Following development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on
immunosuppression and a dose of purified islets, under strict release criteria, transplanted into the Cell Pouch.
A sentinel pouch is removed for an early assessment of the islet transplant. Subjects are followed for additional
safety and efficacy measures for approximately six months. At this point, a decision will be made with regards
to the transplant of a second islet dose with subsequent safety and efficacy follow-up. Following this period,
eligible patients may be administered a single dose of islets through the portal vein. Patients will be then further
followed for one year to assess longer-term safety and efficacy. This study is supported in part by funding from
JDRF, the leading global organization funding type 1 diabetes (T1D) research.
For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more
information on enrollment and recruitment details, please visit www.pwitkowski.org/sernova.
ABOUT SERNOVA'S CELL POUCH SYSTEM
The Cell Pouch system including the Cell Pouch, which is a novel, proprietary, scalable, implantable macro-
encapsulation device solution designed for the long- term survival and function of therapeutic cells. The device
is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and
function of therapeutic cells which then release proteins and hormones as required to treat disease. The Cell
Pouch along with therapeutic cells has been shown to provide long-term safety and efficacy in small and large
animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-
producing cells in humans. In early assessments of its ongoing Phase I/II clinical trial, Sernova has shown
presence of blood levels of c-peptide both during glucose tolerance tests as well as under fasting conditions.
Clinical testing is ongoing at the University of Chicago.
ABOUT SERNOVA CORP
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates",
"believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions
"will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova's management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - February 04, 2021 4 February, 2021
Sernova Shares Accepted for Trading on the Electronic Trading Platform Xetra in Germany
February 4, 2021 9:00 a.m. EST
LONDON, ONTARIO – February 4, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a leading
clinical-stage regenerative medicine therapeutics company, is pleased to announce the start of trading of
Sernova shares on Xetra, the electronic trading system of Deutsche Börse AG in Germany (German
Securities Identification Number (WKN): A0LBCR, International Securities Identification Number (ISIN):
CA81732W1041, German Ticker-Symbol: PSH).
Xetra is an electronic trading platform operated by the Frankfurt Stock Exchange. It offers trading in stocks,
funds, bonds, warrants, and commodities contracts. Launched in 1997, the majority of stock market
transactions in Germany are through the Xetra trading venue: approximately 90 percent of all trading in
shares across all German exchanges is now conducted through Xetra making it the largest of Germany’s
stock exchanges. Over 200 trading participants from 16 European countries, United Arab Emirates and
Hong Kong are connected via Xetra servers.
Xetra is the first and primary choice for institutional investors with its significantly higher liquidity and
narrower price spreads. Given the high turnover (liquidity) on the Xetra trading venue, orders for securities
are executed swiftly and at prices in line with the market. Moreover, this principle is supported by
Designated Sponsors who post binding purchase and selling prices (quotes) continuously and thus ensure
additional liquidity and fair prices, making it the first choice for institutional investors. mwb
Wertpapierhandelsbank AG will act as Designated Sponsor (active market maker) to handle the trading of
Sernova’s shares on Xetra with immediate effect and therefore contribute to increased trading liquidity.
mwb fairtrade Wertpapierhandelsbank AG (www.mwbfairtrade.com) is a securities service provider licensed
by the German Federal Financial Supervisory Authority (BaFin) with branches near Munich, Hamburg,
Hanover, Frankfurt as well as Berlin. Founded in 1993 and active in two business divisions: Securities
Trading and Corporates & Markets, mwb manages approximately 40,000 order books for German and
international securities as well as 89 Designated Sponsors mandates making mwb one of the largest order
book managers in Germany.
“mwb has developed in-depth knowledge on enabling Xetra trading for overseas companies. We are happy
to support Sernova with the rollout of their exciting equity story and look forward to enhance Euro-based
trading possibilities for their institutional and retail investor base in Europe,” said Sascha Guenon, Head of
Designated Sponsoring and Corporate Broking at mwb.
“We are experiencing a significant increase of interest from institutional investors in Europe, especially in
German-speaking countries, and want to provide them with a more efficient way to trade our shares,"
commented Dr. Philip Toleikis, President and CEO of Sernova. "This is an important step to increase the
percentage of long-term oriented institutional investors within our group of shareholders who understand
the potential of our innovative platform technologies in the regenerative medicine field as well as the
valuation gap with our competitors. mwb has a strong network of biotech investors and we are looking
forward to presenting the potential of Sernova’s regenerative medicine platform to them.”
ABOUT SERNOVA
Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-
dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement
of proteins or hormones missing or in short supply within the body. For more information, please visit
www.sernova.com
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are
not historical facts and are generally, but not always, identified by the words “expects”, “plans”,
“anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that
events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the
expectations expressed in such forward-looking statements are based on reasonable assumptions, such
statements are not guarantees of future performance, and actual results may differ materially from those in
forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions
of Sernova’s management on the date such statements were made, which include our beliefs about the
conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or
revise any forward-looking statements whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - February 04, 2021 4 February, 2021
Sernova Upsizes Previously Announced Bought Deal Public Offering to C$20 Million
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
LONDON, ONTARIO – February 4, 2021 – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB:
SEOVF)(FSE: PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to
announce that it has entered into an amendment (the “Amendment”) to its previously announced agreement
with Canaccord Genuity Corp. and Leede Jones Gable Inc., as co-lead underwriters (together, the
“Underwriters”), pursuant to which the Underwriters have agreed to increase the size of the previously
announced bought deal financing. Pursuant to the Amendment, the Underwriters have agreed to purchase, on a
bought deal basis pursuant to the filing of a short form prospectus, an aggregate of 16,700,000 units of the
Company (the “Units”) at a price of C$1.20 per Unit for gross proceeds to the Company of approximately
C$20,040,000 (the “Offering”).
The Company has granted the Underwriters an option (the “Over-allotment Option”), exercisable in part or in
whole at the Underwriters’ discretion, at any time until thirty (30) days following the Closing Date, to purchase
up to the number of additional Units equal to 15% of the aggregate number of Units sold in the Offering to
cover over-allotments, if any.
All other terms of the Offering remain consistent with the Company’s previous announcement on February 3,
2021.
The net proceeds of the Offering will be used to advance the Company’s clinical development program,
including its US Phase I/II Cell Pouch clinical trial, expand Sernova’s research and development programs,
including our local immune protection technologies for the Cell Pouch, as well as for working capital and
general corporate purposes.
The Offering will be completed (i) by way of a short form prospectus to be filed in those provinces of Canada
other than Quebec as the Underwriters and the Company may designate pursuant to National Instrument 44-
101 – Short Form Prospectus Distributions, (ii) on a private placement basis in the United States pursuant to
exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the
“U.S. Securities Act”), and applicable U.S. state securities laws, and (iii) outside Canada and the United States
on a basis which does not require the qualification or registration of any of the Company’s securities under
domestic or foreign securities laws.
The Offering is expected to close on February 24, 2021 and is subject to certain customary conditions including
the approval of the TSX Venture Exchange and applicable securities regulatory authorities.
The securities referred to in this press release have not been, nor will they be, registered under the U.S.
Securities Act or any U.S. state securities laws, and may not be offered or sold within the United States or to, or
for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S.
registration requirements. This press release does not constitute an offer for sale of securities, nor a solicitation
for offers to buy any securities in the United States, nor in any other jurisdiction in which such offer, solicitation
or sale would be unlawful. Any public offering of securities in the United States must be made by means of a
prospectus containing detailed information about the company and management, as well as financial
statements.
About Sernova Corp.
Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells, and stem cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dominic Gray
Sernova Corp
T: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Cautionary Statement Regarding Forward-Looking Information
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities
legislation. These statements relate to future events or future performance. The use of any of the words
“could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements
relating to matters that are not historical facts are intended to identify forward-looking information and are
based on Sernova’s current belief or assumptions as to the outcome and timing of such future events. Forward
looking information in this press release includes information with respect to the Offering, including the timing
and ability of the Company to close the Offering, receipt of all regulatory and stock exchange approvals, the
intended use of proceeds by the Company and the exercise of the Over-allotment Option by the Underwriters.
Forward-looking information is based on reasonable assumptions that have been made by Sernova at the date
of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause
actual results or events to differ materially from those anticipated in the forward-looking information.
Examples of such risk factors include: the inability of the Company to close the Offering or to obtain all
necessary Exchange and regulatory approvals; credit; market (including equity, foreign exchange and interest
rate); liquidity; operational (including technology and infrastructure); reputational; insurance; strategic;
regulatory; legal; environmental; capital adequacy; the general business and economic conditions in the regions
in which the Company operates; the ability of the Company to execute on key priorities, including the
successful development of its product candidates, and strategic plans and to attract, develop and retain key
executives; the ability to implement business strategies and pursue business opportunities; disruptions in or
attacks (including cyber-attacks) on the Company's information technology; the failure of third parties to
comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application
of, current laws and regulations governing the Company’s business; dependence on key suppliers; granting of
permits and licenses; increased competition; changes in foreign currency rates; increased funding costs and
market volatility due to market illiquidity and competition for funding; the availability of funds and resources to
pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods
used by the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from
such events; risks related to COVID-19 including various recommendations, orders and measures of
governmental authorities to try to limit the pandemic, including travel restrictions, border closures,
nonessential business closures, quarantines, self-isolations, shelters-in-place and social distancing, disruptions
to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general
economic conditions including a possible national or global recession; as well as those risk factors disclosed
under the heading “Risk and Uncertainties” in the Company’s annual MD&A (dated February 1, 2021) for the
years ended October 31, 2020 and 2019, which has been filed on SEDAR and is available under the Company’s
profile at www.sedar.com. Given these risks, uncertainties and assumptions, you should not unduly rely on
these forward-looking statements. The forward-looking information contained in this press release is made as
of the date hereof, and Sernova is not obligated to update or revise any forward-looking information, whether
as a result of new information, future events or otherwise, except as required by applicable securities laws. The
foregoing statements expressly qualify any forward-looking information contained herein.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - February 03, 2021 3 February, 2021
Sernova’s Collaborator to Present Cell Pouch™ Thyroid Transplant Study Results at the American Association of Endocrine Surgeons 2021 Annual Meeting
February 3, 2021 - 9:00 a.m. EST
LONDON, ONTARIO – February 3, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a leading
clinical-stage regenerative medicine therapeutics company, is pleased to announce that Dr. Sam Wiseman, BSc,
MD, FRCSC, FACS of the University of British Columbia and co-investigator of Sernova’s Cell Pouch
Hypothyroid treatment program will present preclinical data in an oral presentation at the American Association
of Endocrine Surgeons (AAES) 2021 Annual Meeting taking place April 25-27, 2021. Dr. Sam Wiseman,
Professor, Richard J. Finley Scholar, and Director of Research at the Department of Surgery of Providence
Health Care also serves as Chair of the Endocrine Tumor Group for the Surgical Oncology Network in
Vancouver British Columbia.
Dr. Wiseman’s abstract was selected amongst over 140 abstracts for an Oral Podium Presentation and a
resulting journal article will be peer-reviewed for publication consideration in the journal Surgery.
For more information on the American Association of Endocrine Surgeons and the 41st Annual Meeting, visit
https://meeting.endocrinesurgery.org/.
ABOUT SERNOVA’S HYPOTHYROID PROGRAM
Sernova’s initial approach in treating hypothyroid disease is to transplant a patient’s own healthy thyroid tissue
following thyroidectomy into the pre-implanted vascularized Cell Pouch to recover the normal function of the
thyroid gland. In collaboration with Dr. Wiseman, preclinical proof of concept work is being conducted under a
grant from the British Columbia Transplant Foundation. Following successful completion of preclinical studies,
Sernova plans to conduct clinical assessments of the Cell Pouch with transplanted thyroid tissue in patients
suffering from hypothyroid disease with the aim to preserve thyroid function and improve patient quality of life.
Thyroidectomy is commonly performed for cancer diagnosis or treatment and for treatment of benign (non-
cancerous) disease that includes goiter and hyperthyroidism. It is estimated that about 150,000
thyroidectomies are performed in the US yearly, and the majority of individuals undergoing a thyroid operation
are diagnosed with benign diseases after their procedure. Patients with Grave’s disease and thyroid nodules
undergoing total thyroidectomy, and many patients undergoing partial thyroidectomy require life-long thyroid
hormone medication. Post-surgical thyroid hormone replacement therapy, if monitored carefully, can be
effective; however, patients often suffer from deleterious side-effects including weight gain, depression,
headaches, and cardiovascular disease, with resultant negative impact on quality of life, and significant costs to
the healthcare system. The development of new therapeutic strategies to overcome hypothyroidism remains an
important unmet medical need.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells, and stem cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, hypothyroidism, hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Share the news Partagez les nouvelles
Press Release Communiqué de presse - February 03, 2021 3 February, 2021
Sernova Corp. Announces C$10 Million Bought Deal Offering of Units
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
LONDON, ONTARIO – February 3, 2021 – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB:
SEOVF) (FSE: PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to
announce that it has entered into an agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc., as
the co-lead underwriters (together, the “Underwriters”), pursuant to which the Underwriters have agreed to
purchase, on a bought-deal basis, 8,350,000 units of the Company (the “Units”) at a price of C$1.20 per Unit
(the “Issue Price”) for gross proceeds to the Company of approximately C$10,020,000 (the “Offering”).
Each Unit will consist of one common share of the Company (a “Common Share”) and one Common Share
purchase warrant (a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Common Share at
an exercise price of $1.70 (the “Exercise Price”) at any time up to 24 months following Closing Date (as defined
below). The expiry date of the Warrants may be accelerated by the Company at any time if the volume
weighted average price of the Common Shares on the TSX Venture Exchange (the “Exchange”) is greater than
$3.05 for any ten (10) consecutive trading days, at which time the Company may accelerate the expiry date of
the Warrants by providing notice to holders of Warrants, whereupon the Warrants will expire not less than 30
days after the date of such notice.
The Company has granted the Underwriters an option (the “Over-Allotment Option”), exercisable in part or in
whole at the Underwriters’ discretion, at any time until thirty (30) days following the Closing Date, to purchase
up to the number of additional Units equal to 15% of the aggregate number of Units sold in the Offering to
cover over-allotments, if any.
The Offering will be completed (i) by way of a short form prospectus to be filed in those provinces of Canada
other than Quebec as the Underwriters and the Company may designate pursuant to National Instrument 44-
101 – Short Form Prospectus Distributions, (ii) on a private placement basis in the United States pursuant to
exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the
“U.S. Securities Act”), and applicable U.S. state securities laws, and (iii) outside Canada and the United States
on a basis which does not require the qualification or registration of any of the Company’s securities under
domestic or foreign securities laws.
The net proceeds of the Offering will be used to advance the Company’s clinical development program,
including its US Phase I/II Cell Pouch clinical trial, expand Sernova’s research and development programs,
including our local immune protection technologies for the Cell Pouch, as well as for working capital and
general corporate purposes.
The Underwriters shall be paid (i) a commission (the “Cash Commission”) equal to 6.5% of the aggregate gross
proceeds of the Offering payable in cash or Units, or any combination thereof, at the option of the
Underwriters and (ii) warrants (the “Underwriters’ Warrants”) exercisable at any time up to 24 months following
Closing Date to acquire the number of Units equal to 6.5% of the aggregate number of Units issued pursuant to
the Offering, at an exercise price equal to the Issue Price, other than up to C$500,000 of Units subscribed for
by investors introduced to the Offering by the Company, in which case both the Cash Commission and the
Underwriters’ Warrants will be reduced to 2.0%. Additionally, the Company shall pay the Underwriter’s a
corporate finance fee payable in Units equal to 2.0% of the aggregate number of Units issued pursuant to the
Offering.
The closing of the Offering is expected to occur on or about February 24, 2021 (the “Closing Date”) and is
subject to the Company receiving all necessary regulatory approvals, including the approval of the Exchange.
The securities referred to in this press release have not been, nor will they be, registered under the U.S.
Securities Act or any U.S. state securities laws, and may not be offered or sold within the United States or to, or
for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S.
registration requirements. This press release does not constitute an offer for sale of securities, nor a
solicitation for offers to buy any securities in the United States, nor in any other jurisdiction in which such offer,
solicitation or sale would be unlawful. Any public offering of securities in the United States must be made by
means of a prospectus containing detailed information about the company and management, as well as
financial statements.
About Sernova Corp.
Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e., human donor cells, corrected human cells, and stem cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dominic Gray
Sernova Corp
T: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Cautionary Statement Regarding Forward-Looking Information
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities
legislation. These statements relate to future events or future performance. The use of any of the words
“could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements
relating to matters that are not historical facts are intended to identify forward-looking information and are
based on Sernova’s current belief or assumptions as to the outcome and timing of such future events. Forward
looking information in this press release includes information with respect to the Offering, including the timing
and ability of the Company to close the Offering, receipt of all regulatory and stock exchange approvals, the
exercise of various convertible securities and the intended use of proceeds by the Company. Forward-looking
information is based on reasonable assumptions that have been made by Sernova at the date of the
information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual
results or events to differ materially from those anticipated in the forward-looking information. Examples of
such risk factors include: the inability of the Company to close the Offering or to obtain all necessary Exchange
and regulatory approvals; credit; market (including equity, foreign exchange and interest rate); liquidity;
operational (including technology and infrastructure); reputational; insurance; strategic; regulatory; legal;
environmental; capital adequacy; the general business and economic conditions in the regions in which the
Company operates; the ability of the Company to execute on key priorities, including the successful
development of its product candidates, and strategic plans and to attract, develop and retain key executives;
the ability to implement business strategies and pursue business opportunities; disruptions in or attacks
(including cyber-attacks) on the Company's information technology; the failure of third parties to comply with
their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current
laws and regulations governing the Company’s business; dependence on key suppliers; granting of permits and
licenses; increased competition; changes in foreign currency rates; increased funding costs and market
volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue
operations; critical accounting estimates and changes to accounting standards, policies, and methods used by
the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from such
events; risks related to COVID-19 including various recommendations, orders and measures of governmental
authorities to try to limit the pandemic, including travel restrictions, border closures, nonessential business
closures, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets,
economic activity, financing, supply chains and sales channels, and a deterioration of general economic
conditions including a possible national or global recession; as well as those risk factors disclosed under the
heading “Risk and Uncertainties” in the Company’s annual MD&A (dated February 1, 2021) for the years ended
October 31, 2020 and 2019, which has been filed on SEDAR and is available under the Company’s profile at
www.sedar.com. Given these risks, uncertainties and assumptions, you should not unduly rely on these
forward-looking statements. The forward-looking information contained in this press release is made as of the
date hereof, and Sernova is not obligated to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise, except as required by applicable securities laws. The
foregoing statements expressly qualify any forward-looking information contained herein.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - January 28, 2021 28 January, 2021
Sernova Announces Collaboration Agreements with Multiple Pharmaceutical Industry Leaders
Sernova’s Cell Pouch platform and cell therapy expertise being used in multiple collaborations with global
pharmaceutical companies
January 28, 2021 8:05 a.m. EST
LONDON, ONTARIO – January 28, 2021 – Sernova Corp. (TSX-V: SVA)(OTCQB: SEOVF)(FSE: PSH), a
leading clinical-stage regenerative medicine therapeutics company, announced today that it has entered into
multiple research collaboration agreements with global pharmaceutical companies.
Sernova is deploying its in-house cell therapy expertise and patent-protected Cell Pouch technologies in
combination with proprietary therapeutic cell assets designated by the pharmaceutical collaborators. Further
details of these agreements will be kept confidential for strategic reasons. The collaborators have requested
anonymity.
“The research collaborations follow the ongoing clinical success of Sernova’s Cell Pouch technologies in
diabetes, and reflect the value and evolving recognition of our technologies and cell therapy platform,” said
Dr. Philip Toleikis, President and CEO of Sernova Corp. “These important partnerships with leaders in the
pharma industry build upon Sernova’s business strategy to develop a portfolio of products to realize the full
potential of Sernova’s regenerative medicine platform by extending and broadening its application to new
therapeutic areas and modalities. Sernova’s goal is to provide people with a functional cure for multiple
chronic and rare diseases.”
ABOUT SERNOVA’S CELL POUCH SYSTEM
The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro-
encapsulation device solution designed for the long-term survival and function of therapeutic cells. The
device upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers
for the transplantation and function of therapeutic cells, which then release proteins and hormones as
required to treat disease. The Cell Pouch, along with therapeutic cells, has been shown to provide long-term
safety and efficacy in small and large animal models of diabetes and has been proven to provide a
biologically compatible environment for insulin-producing cells in humans in a Canadian first-in-human
study. Sernova is currently conducting a Phase I/II study at the University of Chicago.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and
immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem cell-derived
cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-
dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement
of proteins or hormones missing or in short supply within the body. For more information, please visit
www.sernova.com.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dominic Gray
Sernova Corp.
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are not recitations of historical facts, may
constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions,
including, without limitation, statements regarding the prospects, plans, and objectives of the company.
Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends",
"estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would",
"may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect
management’s beliefs with respect to future events and are based on information currently available to
management on the date such statements were made. Many factors could cause Sernova’s actual results,
performances or achievements to not be as anticipated, estimated or intended or to differ materially from
those expressed or implied by the forward-looking statements contained in this news release. Such factors
could include, but are not limited to, the company’s ability to secure additional financing and licensing
arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies
for the company’s Cell Pouch System and/or related technologies, including the timing and results of those
trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional
complementary technologies; ability to execute its business strategy and successfully compete in the
market; and the inherent risks associated with the development of biotechnology combination products
generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by
the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings
available on www.sedar.com for additional information on risks and uncertainties relating to the forward-
looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-
looking statements, whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - January 25, 2021 25 January, 2021
Sernova Announces Warrants Exercise for Proceeds of $4.3 Million and Early Conversion of Debenture
LONDON, ONTARIO – January 25, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a leading
clinical-stage regenerative medicine therapeutics company is pleased to announce that in recent weeks it has
received gross proceeds of $4.3 million pursuant to the exercise of more than 14 million warrants. Sernova
intends to use the proceeds of the warrants exercised to support the Company’s clinical diabetes programs
including its US Phase I/II diabetes clinical trial, diabetes stem cell-derived technologies and to also accelerate
treatments for hypothyroid disease and hemophilia A.
The exercised warrants were originally issued in connection to public offerings of units completed by Sernova in
July 2018 and September 2019. In October 2020, the 2018 warrants were subsequently extended by the
Company to February 2021.
Sernova also announces the early conversion by the holder of its outstanding $1 million convertible debenture,
due December 2022, into equity of the Company. The conversion will save the Company almost two years of
interest costs.
“I am extremely pleased to see these warrants being exercised and the continued support from our
shareholders," commented Dr. Philip Toleikis, President and CEO of Sernova Corp. "The early conversion of
the debenture coupled with the warrants proceeds strengthens our balance sheet and cash position as we
continue our ongoing efforts to create shareholder value."
Warrants holders interested in exercising their warrants may contact the Company (see the contact information
provided below). The terms and conditions of the warrants are set out in the warrants certificate.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - January 21, 2021 21 January, 2021
Sernova CEO to Present Regenerative Medicine Therapeutics Platform Update at the 2021 Cell & Gene Meeting on the Med
January 21, 2021 9:00 a.m. EST
LONDON, ONTARIO – January 21, 2021 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical-
stage regenerative medicine company announced today that Dr. Philip Toleikis, President and CEO has been
invited to participate at the Cell & Gene Virtual Meeting on the Med, and available on-demand to attendees
beginning Thursday, April 6 to 9. Dr. Toleikis will deliver a corporate update on Sernova’s regenerative medicine
therapeutics platform including our US clinical cell therapy diabetes program as part of the 2021 Company
Presentations at the Cell & Gene Meeting on the Med.
Sernova’s Corporate Update presentation will be available on-demand to attendees of the Virtual Cell & Gene
Meeting on the Med throughout the conference. For more details on Sernova’s presentation, please visit
www.meetingonthemed.com.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutic solutions using a medical device (Cell Pouch™)
and immune protected therapeutic cells/tissues (i.e., human donor cells, corrected human cells and stem cell-
derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as
insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through cellular
production of proteins or hormones missing or in short supply within the body. For more information, please
visit www.sernova.com.
ABOUT SERNOVA’S CELL POUCH™ SYSTEM
The Cell Pouch™, as part of the Cell Pouch™ System, is a novel, proprietary, scalable, implantable macro-
encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device
upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the
transplantation and function of therapeutic cells, which then release proteins and hormones as required to
treat disease. The Cell Pouch™, along with therapeutic cells, has been shown to provide long-term safety and
efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible
environment for insulin-producing cells in humans in a Canadian first-in-human study. Sernova is currently
conducting a Phase I/II study at the University of Chicago.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dominic Gray
Sernova Corp.
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are not recitations of historical facts, may constitute
“forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without
limitation, statements regarding the prospects, plans, and objectives of the Company. Wherever possible, but
not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects",
"potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should"
occur are used to identify forward-looking statements. These statements reflect management’s beliefs with
respect to future events and are based on information currently available to management on the date such
statements were made. Many factors could cause Sernova’s actual results, performances or achievements to
not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such factors could include, but are not limited to,
the Company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all;
ability to conduct all required preclinical and clinical studies for the Company’s Cell Pouch System and/or
related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory
approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute
its business strategy and successfully compete in the market; and the inherent risks associated with the
development of biotechnology combination products generally. Many of the factors are beyond our control,
including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult
the Company’s quarterly and annual filings available on www.sedar.com for additional information on risks and
uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or
obligation to update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - January 15, 2021 15 January, 2021
Sernova Principal Investigator Presents Additional Positive Preliminary Safety and Efficacy Data from Ongoing U.S. Phase I/II Cell Pouch Clinical Trial for Type-1 Diabetes
Sernova’s Cell Pouch System shows sustained clinical benefit in study patients with type 1 diabetes through
multiple efficacy indicators and ongoing safety and tolerability
January 15, 2021 2:05 p.m. EST
LONDON, ONTARIO – January 15, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a leading
clinical-stage regenerative medicine therapeutics company today announced that its principal clinical
investigator, Dr. Piotr Witkowski, presented additional positive preliminary safety and efficacy data at the 2021
American Society of Transplant Surgeons Winter Symposium. Sernova’s Cell Pouch™ transplanted with insulin
producing cells in patients with type 1 diabetes continues to show persistent islet function and clinically
meaningful improvement in measures of glucose control.
Dr. Witkowski highlighted the following key points in his presentation:
• 5 of 7 patients are currently enrolled in the study.
o 5 of 7 patients have been implanted with the Cell Pouch
o 3 of 7 patients have received their first/one islet transplant
o 2 of 7 patients have received their first and second islet transplant
o The remaining 2 patients are actively being pre-screened to complete trial enrolment
The overall objective of the study is to assess the safety, tolerability, and efficacy of the Cell Pouch with insulin-
producing islets. In addition to other criteria, prior to entry into the study, the patients must demonstrate long-
standing type 1 diabetes with severe hypoglycemic unawareness episodes and no glucose-stimulated C-peptide
circulating in their bloodstream.
In his presentation, aside from confirming ongoing safety and tolerability in all currently enrolled patients, Dr.
Witkowski focused on the first transplanted patients who are furthest in the study and who have received a
second islet transplant. Importantly, these patients are showing defined clinical benefit with a clinically
meaningful reduction in daily injectable insulin requirement, along with the following additional ongoing efficacy
indicators:
• Absence of life threatening severe hypoglycemic events;
• Sustained blood levels of C-peptide (a biomarker for insulin produced by cells in the Cell Pouch);
• Reduction in HbA1c (a measure of long-term glucose control); and,
• Improvement in overall Continuous Glucose Monitoring (CGM) measured glucose control parameters (e.g.,
blood glucose ‘Time in Range’).
With the positive clinical benefit achieved in patients with Cell Pouch islets, one patient was later provided a
single infusion of islets (portal vein). This top-up to the islets already received in the Cell Pouch contributed to
this patient achieving and sustaining insulin independence. This patient has now been insulin free (requiring no
injectable insulin) for nine months with optimal glucose control.
“I am pleased with the invitation to present additional positive preliminary clinical trial results to my esteemed
peers at the 2021 ASTS meeting,” said Dr. Witkowski. “While we continue to validate the therapeutic potential
of Sernova’s Cell Pouch with islets for type 1 diabetes, we also continue to optimize conditions within the
designed clinical protocol towards a therapy to provide to diabetic patients, as we observe ongoing safety and
efficacy measures in our trial patients. I am excited to be part of this evolution in patient treatment as we
advance the Cell Pouch cell therapy approach towards a functional cure for diabetes.”
ABOUT SERNOVA’S CLINICAL TRIAL
Sernova is conducting a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial, to assess
the safety and tolerability of islet transplantation into the company’s patented Cell Pouch in diabetic subjects
with hypoglycemia unawareness and an inability to produce their own insulin. The secondary objective is to
assess efficacy through a series of defined measures.
Eligible subjects are implanted with Cell Pouches. Following development of vascularized tissue chambers
within the Cell Pouch, subjects are then stabilized on immunosuppression and a dose of purified islets, under
strict release criteria, transplanted into the Cell Pouch.
A sentinel pouch is removed for an early assessment of the islet transplant. Subjects are followed for additional
safety and efficacy measures for approximately six months. At this point, a decision will be made with regards
to the transplant of a second islet dose with subsequent safety and efficacy follow up. Following this period,
eligible patients may be administered a single dose of islets through the portal vein. Patients will be then further
followed for one year to assess longer-term safety and efficacy.
This study is supported in part by funding from JDRF, the leading global organization funding type 1 diabetes
(T1D) research.
For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more
information on enrollment and recruitment details please visit www.pwitkowski.org/sernova.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Contact Us Contactez-nous
Business
Development
Développement des affaires
Dr. Philip Toleikis
Sernova Corp.
1.519.858.5184
info@sernova.com
Corporate Communications, Investor Relations and Media Relations Communications d'entreprise, relations avec les investisseurs et relations avec les médias
Dominic Gray
Sernova, Corp.
1.519.858.5126
info@sernova.com
About UsL'entreprise
Company OverviewPrésentation de l'entreprise
ManagementLa gestion
Board of DirectorsConseil d'administration
PartnersLes partenaires
Company MilestonesJalons de l'entreprise
TechnologyTechnologie
Regenerative MedicineMédecine régénérative
Cell Pouch System™Cell Pouch System™
Immune Protection TechnologyImmuno-Protection
IndicationsLes Indications
Therapeutic PipelinePipeline Thérapeutique
Clinical StudiesEtudes cliniques
InvestorInvestisseur
Investor PresentationsPrésentation investisseurs
News ReleasesCommuniqués de presse
Latest Updates/Videos/FeaturesDernières mises à jour / vidéos / fonctionnalités
Financial Report and Other FilingsRapport financier et autres dépôts
EventsÉvénements
Analyst CoverageCouverture des analystes
Stock InfoInformations sur le stock
Company MilestonesJalons de l'entreprise
Corporate GovernanceGouvernance d'entreprise
About Sernova.com A propos de Sernova.com
Sernova Corp (TSX-V: SVA) is a clinical stage (US FDA; Health Canada) company, developing disruptive platform technologies to treat chronic diseases through a regenerative medicine approach. Sernova’s primary focus is in developing technologies for the treatment of patients with insulin-dependent (TI) diabetes, hemophilia A and thyroid disease. Sernova Corp (TSX-V: SVA) est une société en phase clinique (US FDA; Santé Canada) développant des applications thérapeutiques afin de traiter les maladies chroniques grâce à une approche régénérative. L’objectif principal de Sernova est de développer des technologies pour le traitement des patients atteints de diabète insulino-dépendant (T1), d’hémophilie A et de maladie de la glande thyroïde.
Please read our Legal Notice and Privacy Policy which includes information about Disclaimers and Terms of Use. Veuillez lire notre notice légale et notre politique de confidentialité, qui comprennent des informations sur les clauses de non-responsabilité et les conditions d'utilisation.
Career OpportunitiesOpportunités de carrière
See our latest job posting and long-term career opportunities: Voir nos dernières offres d'emploi et opportunités de carrière à long terme:
Career Opportunities pagePage web Opportunités de carrière
Follow us Suivez nous
All content is copyright
Tout le contenu est copyright
© 2001 - 2021 Sernova, Corp.
All content is copyright Tout le contenu est copyright © 2001 - 2021 Sernova, Corp.